Merck, Bristol Myers Squibb, Sanofi and Roche — were eager to position themselves as fully prepared for whatever may come ...

The grow­ing drug dis­count pro­gram for low-in­come Amer­i­cans, known as the 340B pro­gram, has “trans­paren­cy and ...

Lotte Biologics, Ypsomed, PCI Pharma, Samsung Biologics, Catalent & Ferring share manufacturing updates: new ADC services, ...

Thermo Fisher Scientific has warned it could lose out on nearly $1 billion in revenue this year due to the US-China tariff ...

Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported ...

Tempus AI expands deals with AstraZeneca and Pathos for $200M, Avidicure raises $50M seed round, Bioxodes reports Phase 2a ...

San Diego biotech Halozyme is suing Merck over an injectable version of its blockbuster cancer drug, alleging that the new formulation will infringe on Halozyme's under-the-skin delivery patents.

Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China.

Roche details plans to handle US tariffs, including moving production and building inventory, while Sanofi runs scenarios but ...

But the company is not ruling out future deals, even in its metabolic unit, which recently saw a major partnership with ...

Morgan Cheatham joins Breyer Capital as healthcare head, discusses AI virtual labs' potential in drug discovery.

As­traZeneca CEO Pas­cal So­ri­ot called on Eu­rope to step up in­vest­ments and “pro­tect its health sov­er­eign­ty” as it ...